Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ashtead reiterates outlook on 'solid' first-quarter trading

(Sharecast News) - Construction equipment rental specialist Ashtead Group reiterated its full-year outlook on Wednesday, despite a dip in first-quarter earnings.

Revenues at the blue chip - which is in the process of moving its primary listing to New York - improved 2% to $2.8bn in the three months to 31 July.

Rental revenues were also 2% higher, at $2.6bn, as mega project activity gained momentum.

Adjusted earnings before interest, tax, depreciation and amortisation eased 1% to $1.3bn, however, due to lower used equipment sales, while depreciation charges saw pre-profits fall 6% to $512m.

But looking to the full year, and Ashtead reiterated its outlook for rental revenue growth of between 0% and 4%.

Free cash flow was also forecast to come in between $2.2bn and $2.5bn, up from previous guidance of between $2bn and $2.3bn, due to changes in US tax legislation.

Brendan Horgan, chief executive, said: "The group delivered solid first-quarter results, with results, profits and free cashflow in line with our expectations, as we take advantage of secular tailwinds and the structural progression of our industry."

Horgan added that the Wall Street listing was on track for March 2026.

The move is widely seen as a blow to the London stock market, as it battles to attract and retain international companies. Although Ashtead will retain a UK listing, it will exit the FTSE 100 once the move is complete.

Ashtead makes nearly all of its profits in the US.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.